VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
-2.24%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.69B
AUM Growth
+$419M
(+33%)
Cap. Flow
+$502M
Cap. Flow
% of AUM
29.74%
Top 10 Holdings %
Top 10 Hldgs %
42.19%
Holding
93
New
24
Increased
33
Reduced
11
Closed
18
Top Buys
| 1 |
Merck
MRK
|
$79.6M |
| 2 |
Nuvalent
NUVL
|
$47M |
| 3 |
Vera Therapeutics
VERA
|
$45.5M |
| 4 |
Cytokinetics
CYTK
|
$40M |
| 5 |
Ascendis Pharma
ASND
|
$37.2M |
Top Sells
| 1 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$63.9M |
| 2 |
Insmed
INSM
|
$48.3M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$33.8M |
| 4 |
uniQure
QURE
|
$30.5M |
| 5 |
Janux Therapeutics
JANX
|
$22M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Intellia Therapeutics
NTLA
$1.25B
| $6.12M | 0.36% |
+525,000
| New | +$6.12M |
|
|
OKUR
52
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$36.4M
| $5.46M | 0.32% |
635,000
+555,060
| +694% | +$4.77M |
|
53
Galapagos
GLPG
$2.1B
| $4.95M | 0.29% |
180,000
| – | – |
|
|
CMRX
54
DELISTED
Chimerix, Inc.
CMRX
| $4.87M | 0.29% |
1,400,000
| – | – |
|
55
Sutro Biopharma
STRO
$86.5M
| $4.73M | 0.28% |
+2,570,000
| New | +$4.73M |
|
56
Ventyx Biosciences
VTYX
$185M
| $4.38M | 0.26% |
2,000,000
+275,000
| +16% | +$602K |
|
57
Fate Therapeutics
FATE
$112M
| $4.07M | 0.24% |
2,465,000
+780,000
| +46% | +$1.29M |
|
58
Alto Neuroscience
ANRO
$95M
| $3.87M | 0.23% |
915,000
+265,000
| +41% | +$1.12M |
|
|
VERV
59
DELISTED
Verve Therapeutics
VERV
| $3.64M | 0.22% |
645,000
+120,000
| +23% | +$677K |
|
60
Passage Bio
PASG
$22.3M
| $3.46M | 0.21% |
305,000
| – | – |
|
61
Allogene Therapeutics
ALLO
$246M
| $3.2M | 0.19% |
1,500,000
| – | – |
|
62
Transmedics
TMDX
$3.55B
| $3.12M | 0.18% |
+50,000
| New | +$3.12M |
|
63
Monte Rosa Therapeutics
GLUE
$303M
| $2.95M | 0.17% |
425,000
-505,000
| -54% | -$3.5M |
|
64
Zymeworks
ZYME
$1.07B
| $2.71M | 0.16% |
185,000
-430,000
| -70% | -$6.3M |
|
65
enGene Holdings
ENGN
$256M
| $2.46M | 0.15% |
+370,000
| New | +$2.46M |
|
66
Bausch Health
BHC
$2.67B
| $2.02M | 0.12% |
+250,000
| New | +$2.02M |
|
67
Neurogene
NGNE
$280M
| $1.83M | 0.11% |
+80,000
| New | +$1.83M |
|
|
ACHL
68
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $1.71M | 0.1% |
1,500,000
| – | – |
|
69
Atara Biotherapeutics
ATRA
$89.9M
| $1.66M | 0.1% |
125,000
+323
| +0.3% | +$4.3K |
|
70
Immunovant
IMVT
$2.81B
| $1.11M | 0.07% |
+45,000
| New | +$1.11M |
|
71
MacroGenics
MGNX
$123M
| $910K | 0.05% |
280,000
-550,000
| -66% | -$1.79M |
|
72
Traws Pharma
TRAW
$11.8M
| $666K | 0.04% |
+75,000
| New | +$666K |
|
73
Tenax Therapeutics
TENX
$27.4M
| $342K | 0.02% |
55,189
-28,144
| -34% | -$174K |
|
|
74
Agios Pharmaceuticals
AGIO
$2.1B
| – | – |
-760,000
| Closed | -$33.8M |
|
75
Apogee Therapeutics
APGE
$2.21B
| – | – |
-136,500
| Closed | -$8.02M |
|